GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Purple Biotech Ltd (XTAE:PPBT) » Definitions » Deferred Policy Acquisition Costs

Purple Biotech (XTAE:PPBT) Deferred Policy Acquisition Costs


View and export this data going back to 1978. Start your Free Trial

What is Purple Biotech Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Purple Biotech Business Description

Industry
Traded in Other Exchanges
Address
4 Oppenheimer Street, Science Park, Rehovot, ISR, 7670104
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.